167 related articles for article (PubMed ID: 25708267)
21. Clinically-staged T3N0 rectal cancer: is preoperative chemoradiotherapy the optimal treatment?
Lombardi R; Cuicchi D; Pinto C; Di Fabio F; Iacopino B; Neri S; Tardio ML; Ceccarelli C; Lecce F; Ugolini G; Pini S; Di Tullio P; Taffurelli M; Minni F; Martoni A; Cola B
Ann Surg Oncol; 2010 Mar; 17(3):838-45. PubMed ID: 20012700
[TBL] [Abstract][Full Text] [Related]
22. Upregulation of stromal cell-derived factor 1α expression is associated with the resistance to neoadjuvant chemoradiotherapy of locally advanced rectal cancer: angiogenic markers of neoadjuvant chemoradiation.
Kim HJ; Bae SB; Jeong D; Kim ES; Kim CN; Park DG; Ahn TS; Cho SW; Shin EJ; Lee MS; Baek MJ
Oncol Rep; 2014 Dec; 32(6):2493-500. PubMed ID: 25241658
[TBL] [Abstract][Full Text] [Related]
23. [Detection and clinical significance of apoptosis related protein in local advanced rectal cancer patients with preoperative neoadjuvant therapy].
Liu Y; Zhang G; Qian J; Zhu YP; Ju HX; Feng HY; Zhu HN; Li DC
Zhonghua Wai Ke Za Zhi; 2012 Oct; 50(10):914-7. PubMed ID: 23302463
[TBL] [Abstract][Full Text] [Related]
24. Expression of HER-2 in rectal cancers treated with preoperative radiotherapy: a potential biomarker predictive of metastasis.
Yao YF; Du CZ; Chen N; Chen P; Gu J
Dis Colon Rectum; 2014 May; 57(5):602-7. PubMed ID: 24819100
[TBL] [Abstract][Full Text] [Related]
25. Autophagy-related proteins LC3 and Beclin-1 impact the efficacy of chemoradiation on esophageal squamous cell carcinoma.
Chen Y; Li X; Wu X; He C; Guo L; Zhang S; Xiao Y; Guo W; Tan B
Pathol Res Pract; 2013 Sep; 209(9):562-7. PubMed ID: 23880165
[TBL] [Abstract][Full Text] [Related]
26. Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival.
Sprenger T; Conradi LC; Beissbarth T; Ermert H; Homayounfar K; Middel P; Rüschoff J; Wolff HA; Schüler P; Ghadimi BM; Rödel C; Becker H; Rödel F; Liersch T
Cancer; 2013 Jan; 119(1):26-35. PubMed ID: 22736392
[TBL] [Abstract][Full Text] [Related]
27. The prognostic value of tumour regression grade following neoadjuvant chemoradiation therapy for rectal cancer.
Abdul-Jalil KI; Sheehan KM; Kehoe J; Cummins R; O'Grady A; McNamara DA; Deasy J; Breathnach O; Grogan L; O'Neill BD; Faul C; Parker I; Kay EW; Hennessy BT; Gillen P
Colorectal Dis; 2014 Jan; 16(1):O16-25. PubMed ID: 24119076
[TBL] [Abstract][Full Text] [Related]
28. Statin therapy is associated with improved pathologic response to neoadjuvant chemoradiation in rectal cancer.
Mace AG; Gantt GA; Skacel M; Pai R; Hammel JP; Kalady MF
Dis Colon Rectum; 2013 Nov; 56(11):1217-27. PubMed ID: 24104995
[TBL] [Abstract][Full Text] [Related]
29. Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation.
Lin CY; Tian YF; Wu LC; Chen LT; Lin LC; Hsing CH; Lee SW; Sheu MJ; Lee HH; Wang YH; Shiue YL; Wu WR; Huang HY; Hsu HP; Li CF; Chen SH
J Clin Pathol; 2012 Aug; 65(8):687-92. PubMed ID: 22569540
[TBL] [Abstract][Full Text] [Related]
30. Thymidine phosphorylase and hypoxia-inducible factor 1-α expression in clinical stage II/III rectal cancer: association with response to neoadjuvant chemoradiation therapy and prognosis.
Lin S; Lai H; Qin Y; Chen J; Lin Y
Int J Clin Exp Pathol; 2015; 8(9):10680-8. PubMed ID: 26617778
[TBL] [Abstract][Full Text] [Related]
31. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
Arbea L; Martínez-Monge R; Díaz-González JA; Moreno M; Rodríguez J; Hernández JL; Sola JJ; Ramos LI; Subtil JC; Nuñez J; Chopitea A; Cambeiro M; Gaztañaga M; García-Foncillas J; Aristu J
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):587-93. PubMed ID: 22079731
[TBL] [Abstract][Full Text] [Related]
32. Transanal endoscopic microsurgery for residual rectal cancer (ypT0-2) following neoadjuvant chemoradiation therapy: another word of caution.
Perez RO; Habr-Gama A; Lynn PB; São Julião GP; Bianchi R; Proscurshim I; Gama-Rodrigues J
Dis Colon Rectum; 2013 Jan; 56(1):6-13. PubMed ID: 23222274
[TBL] [Abstract][Full Text] [Related]
33. Clinical prediction of pathological complete response after preoperative chemoradiotherapy for rectal cancer.
Huh JW; Kim HR; Kim YJ
Dis Colon Rectum; 2013 Jun; 56(6):698-703. PubMed ID: 23652742
[TBL] [Abstract][Full Text] [Related]
34. Magnetic resonance imaging in rectal cancer downstaged using neoadjuvant chemoradiation: accuracy of prediction of tumour stage and circumferential resection margin status.
Kulkarni T; Gollins S; Maw A; Hobson P; Byrne R; Widdowson D
Colorectal Dis; 2008 Jun; 10(5):479-89. PubMed ID: 18318754
[TBL] [Abstract][Full Text] [Related]
35. ALDH1 is a prognostic factor for patients treated with neoadjuvant chemoradiotherapy and radical resection for stage III rectal cancer.
Oh SY; Sohn SH; Yim H; Lee D; Suh KW; Kim YB
J Surg Oncol; 2015 Feb; 111(2):243-7. PubMed ID: 25270363
[TBL] [Abstract][Full Text] [Related]
36. Potential Prognostic Factors of Downstaging Following Preoperative Chemoradiation for High Rectal Cancer.
Treder M; Vogelsang RP; Janssen S; Schild SE; Holländer NH; Rades D
In Vivo; 2018; 32(6):1481-1484. PubMed ID: 30348705
[TBL] [Abstract][Full Text] [Related]
37. Clinical implications of acellular mucin pools in resected rectal cancer with pathological complete response to neoadjuvant chemoradiation.
de Campos-Lobato LF; Dietz DW; Stocchi L; Vogel JD; Lavery IC; Goldblum JR; Skacel M; Pelley RJ; Kalady MF
Colorectal Dis; 2012 Jan; 14(1):62-7. PubMed ID: 21176057
[TBL] [Abstract][Full Text] [Related]
38. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
[TBL] [Abstract][Full Text] [Related]
39. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
[TBL] [Abstract][Full Text] [Related]
40. Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.
Balboa E; Duran G; Lamas MJ; Gomez-Caamaño A; Celeiro-Muñoz C; Lopez R; Carracedo A; Barros F
Pharmacogenomics; 2010 Jun; 11(6):747-61. PubMed ID: 20504250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
